ArticleInternational journal of microbiology2025
Ultrasound-Stimulated Microbubble Cavitation Combined With Anti-PD-L1 Blockade Inhibits the Progression of MC38 Tumors and Alters the Composition of Gut Microbiota in Mice.
Article in International journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PD-L1 inhibitor immunotherapies have achieved significant advances in cancer treatment, yet only a subset of patients benefits, with response rates varying widely. Previous studies demonstrated that ultrasonic-stimulated microbubble cavitation (USMC) enhances the antitumor effects of PD-L1 inhibitors, suppressing tumor progression and prolonging survival in murine models. Given the gut microbiome's critical role in antitumor immunity and treatment efficacy, the interplay between USMC, immunotherapy, and gut microbiota remains poorly understood. To investigate this relationship, we conducted 16S rDNA sequencing to analyze the gut microbiota in mice across four treatment groups: control (ck), USMC group (um), PD-L1 inhibitor (pdl1), and USMC+PD-L1 inhibitor (um-pdl1). Our results revealed significant variations in gut microbial composition and abundance among the groups. Notably, we identified a correlation between commensal microbiota profiles and therapeutic responses. Mice treated with pdl1 alone or in combination with um exhibited marked reductions in tumor volume and weight, along with prolonged survival and concurrent shifts in gut microbiota. Multimatrix correlation analysis further identified four bacterial genera (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.